In this issue of Seminars in Cutaneous Medicine and Surgery, we focus on providing readers with a comprehensive understanding of the current state of knowledge, as well as major knowledge gaps, of HS.
This review will focus on the outcome measures driving clinical research in hidradenitis suppurativa, as well as existing data on systemic agents used in medical management of hidradenitis suppurativa, including antibiotics, hormonal therapies, and biologics.
Advances in laser technology, combined with their increasing versatility in the management of dermatologic conditions, have sparked interest in their utility for HS patients.
All skin diseases involve some element of stigmatization and psychosocial consequence for the individual patient, but few, if any, skin diseases can match the impact of hidradenitis suppurativa (HS) on the patient.
Repeated episodes of profound inflammation in HS can lead to a number of complications in patients who are often otherwise young, active, and healthy.
This paper outlines the current major questions and research gaps in HS, updated from van der Zee et al and Ingram et al and suggests some initial approaches to address each of these gaps.